Indrayani Biotech Approves Key Documents for ₹49.9 Cr Rights Issue

The company's Rights Issue Committee has approved crucial documents, including the Letter of Offer (LOF), for its ₹49.90 crore rights issue. The issue price is set at ₹15 per share, with a 5:7 entitlement ratio.

Key Documents Signed Off

Indrayani Biotech Limited's Rights Issue Committee met on April 28, 2026. During this meeting, the committee formally approved essential documentation for the proposed ₹49.90 crore rights issue. Key documents endorsed include the Letter of Offer (LOF), Abridged Letter of Offer (ALOF), and the Composite Application Form (CAF). These approvals advance the company's plan to raise fresh capital.

Why Indrayani Biotech Needs Funds

This rights issue aims to inject funds into Indrayani Biotech to strengthen its working capital and cover general corporate purposes. It signals the company's strategy to fund operations and growth through equity. For shareholders, this means an expansion of the equity base and potential dilution, alongside capital that could support future value.

History of Rights Issues

Indrayani Biotech has previously used rights issues for financing. In 2023, it raised approximately ₹25 crore at ₹10 per share, also for working capital and general needs. This new ₹49.90 crore issue follows that pattern. The company operates across food and hospitality, dairy, healthcare, agriculture, and infrastructure.

What Happens Next

The approval allows the formal offer document to be filed with regulatory bodies. Eligible shareholders will receive their rights entitlements soon. The company moves closer to securing funds for operational and strategic objectives. The company's equity base will expand upon successful subscription and payment.

Financial Health and Risks

Indrayani Biotech has a promoter holding of 33.3%. The company has a return on equity of 5.79% over three years and a high debt-to-equity ratio of 140.81%. Working capital days increased to 211. Profitability has fluctuated, with a reported loss of ₹6 crore for FY25 after a profit in FY24. The company has a history of increasing its equity base through rights issues, which can lead to dilution for existing investors.

Competitive Landscape

Indrayani Biotech operates in diverse sectors, making direct peer comparison challenging. In agri-business, peers like Kaveri Seed Co. are larger. In food, LT Foods and KRBL are also larger. Indrayani Biotech's market capitalization is ₹55 Crores, below the median peer market cap of ₹94 Crores. While peers like Kaveri Seed Co. and LT Foods show stronger financial metrics and market presence, Indrayani Biotech focuses on consolidating smaller entities.

Recent Financials

Revenue for FY24 was ₹167 crore, with a net income of ₹10 crore. For FY25, the company reported a net loss of ₹6 crore. The Debt to Equity ratio was approximately 140.81% on a trailing twelve months basis. Working capital days increased to 211 days as of FY25.

Looking Ahead

Shareholders should monitor the official filing of the Letter of Offer with SEBI and stock exchanges. They should also track subscription levels once the rights issue opens on May 27, 2026. Monitoring the utilization of raised funds and the company's ability to improve profitability post-issue will be key. Future announcements regarding payment schedules for partly paid-up shares should also be watched.